Examkin

Question

Difficulty: MediumImmunologic and Inflammatory Processes

A 54-year-old woman comes to the clinic due to persistent joint pain and morning stiffness. She was diagnosed with rheumatoid arthritis two years ago and has been taking oral methotrexate, but her symptoms remain poorly controlled. Physical examination shows active synovitis and effusion in the bilateral metacarpophalangeal and proximal interphalangeal joints. The physician plans to initiate a tumor necrosis factor (TNF) alpha inhibitor. Before starting the new medication, an interferon-gamma release assay is obtained and is positive. A chest radiograph shows no abnormalities, and she has no cough, night sweats, or weight loss. The physician decides to delay the biologic therapy and initiates a course of rifampin. The proposed biologic therapy increases the risk of disease reactivation in this patient by directly impairing which of the following immunologic processes?

  1. A
    Opsonization of encapsulated organisms via complement activation
  2. B
    Migration of polymorphonuclear leukocytes to sites of acute inflammation
  3. Maintenance of macrophage-rich organized cellular aggregatesAnswer
  4. D
    Central maturation and selection of cytotoxic T lymphocytes
  5. E
    Antigen-driven isotype switching of B lymphocytes

Answer

Maintenance of macrophage-rich organized cellular aggregates
The correct answer identifies the maintenance of macrophage-rich organized cellular aggregates (granulomas). The patient's positive IGRA and asymptomatic presentation indicate latent tuberculosis infection (LTBI). In LTBI, Mycobacterium tuberculosis is contained within caseating granulomas in the lungs. Tumor necrosis factor-alpha (TNF-alpha), secreted primarily by macrophages and T cells, is a critical cytokine that sustains macrophage activation and maintains the architectural integrity of these granulomas. The use of a TNF-alpha inhibitor disrupts this delicate balance, leading to the dissolution of the granuloma and subsequent reactivation and dissemination of the mycobacteria. Consequently, patients must be screened for and treated for LTBI prior to starting TNF-alpha inhibitor therapy.

Step-by-Step Solution

1
Interpret the pre-treatment screening results.
The patient has a positive interferon-gamma release assay (IGRA) with a normal chest radiograph and no systemic symptoms, confirming a diagnosis of latent tuberculosis infection (LTBI).
Screening for latent tuberculosis is mandatory before initiating biologic therapies that suppress cell-mediated immunity.
2
Identify the pharmacologic target of the proposed therapy.
The planned medication is a TNF-alpha inhibitor.
Understanding the drug class allows correlation with its specific immunologic effects.
3
Correlate the mechanism of the drug with the underlying pathology of the infection.
TNF-alpha is essential for activating macrophages and maintaining the structural integrity of caseating granulomas. Inhibiting TNF-alpha will cause granuloma breakdown, leading to the reactivation of latent tuberculosis.
This explains the physiological basis for the absolute contraindication of starting TNF-alpha inhibitors prior to treating LTBI.

Key Concept

Tumor necrosis factor-alpha (TNF-alpha) is vital for the maintenance of granulomas in latent tuberculosis; administration of TNF-alpha inhibitors disrupts this immunologic process, predisposing patients to life-threatening reactivation of the disease.
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic